Pharmaceutical Processing World

Since its establishment in 1984, Pharmaceutical Processing has been a key resource for professionals in the pharmaceutical, biopharmaceutical, and biotech sectors, offering updates, insights, and information on the latest technologies and services. From the stages of formulation to packaging and advanced manufacturing, Pharmaceutical Processing World delivers thorough coverage of the newest innovations and best practices in the industry. The publication also provides in-depth analysis on various aspects of the pharmaceutical sector, including new product launches, drug pricing trends, treatment developments, and regulatory updates. Each year, we feature the Big Pharma 50, which highlights the largest pharmaceutical companies and offers valuable information about their research and development investments, top-selling medications, and future drug candidates. Pharmaceutical Processing World’s editorial content addresses important issues in pharmaceutical manufacturing, covering topics such as outsourcing, contract development, smart manufacturing, and the advancements associated with Industry 4.0. We also delve into areas like biologics, biopharmaceutical products, and innovation within the pharmaceutical field. Our audience consists of chemical engineers, technicians, facility managers, and regulatory experts.

Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#2491894

United States

#1179267

Health/Biotechnology and Pharmaceuticals

#1118

Traffic sources

Monthly visitors

Articles

Pharma ingredient manufacturer Antheia raises $56M Series C

4 days ago | pharmaceuticalprocessingworld.com | Sean Whooley

Pharmaceutical ingredient manufacturer Antheia announced today that it raised $56 million in Series C financing. The Menlo Park, California-based company aims to deliver ingredients to transform essential medicine supply chains. It plans to use the financing to expand the commercialization of its first product, Thebaine. The company also plans to launch additional products from its pipeline of more than 70 biosynthetic pharmaceutical ingredients.
Driving success in fast-paced high-tech pharma construction projects

1 week ago | pharmaceuticalprocessingworld.com | Brian Buntz

Getting a manufacturing plant from investment to start-up as quickly as possible is a priority in almost every industry. Yet speed-to-market is even more important when it comes to a biotech or pharmaceutical facility. When going online means getting a lifesaving or health-improving solution into the hands of the people who need them, a heightened sense of urgency and care should guide every step of the project.
Prolific Machines enters FDA program to enhance therapeutics manufacturing platform

2 weeks ago | pharmaceuticalprocessingworld.com | Danielle Kirsh

Prolific Machines, a biotechnology firm developing optogenetics-based solutions for protein manufacturing, has been accepted into the FDA’s Emerging Technology Program, the company announced this week. The FDA’s Center for Drug Evaluation and Research (CDER) program supports the adoption of novel manufacturing technologies with the potential to improve drug quality and availability.
Roche, Genentech to build $700M plant in North Carolina

3 weeks ago | pharmaceuticalprocessingworld.com | Sean Whooley

Roche and its Genentech unit today announced plans to invest more than $700 million in a new manufacturing facility in the U.S.The company plans to build a new 700,000 square-foot, state-of-the-art drug manufacturing plant in Holly Springs, North Carolina. It expects to add more than 400 high-wage manufacturing jobs once operational, plus more than 1,500 construction jobs during site development. Holly Springs is located just outside Raleigh in the “Research Triangle” region of North Carolina.
ICU Medical, Otsuka launch joint IV supply chain venture

1 month ago | pharmaceuticalprocessingworld.com | Sean Whooley

ICU Medical and Otsuka Pharmaceutical Factory (OPF) announced the formation of a new joint venture to strengthen supply chain resiliency. In this joint venture, the companies say they formed Otsuka ICU Medical LLC. It aims to strengthen IV solutions supply chains and drive innovation in the North American market. The joint venture follows last year’s agreement that saw ICU Medical aid Otsuka in entering the U.S. IV market.
Amgen to spend $900M to expand U.S. biopharma manufacturing

1 month ago | pharmaceuticalprocessingworld.com | Sean Whooley

Amgen announced that it plans to invest $900 million to expand its pharmaceutical manufacturing facility in Ohio. The expansion brings the total number of jobs created to 750. Amgen’s total investment in Central Ohio now eclipses $1.4 billion. “Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement

1 month ago | pharmaceuticalprocessingworld.com | Chris Newmarker

Fujifilm Diosynth Biotechnologies, a major contract development and manufacturing organization (CDMO), has entered into a 10-year manufacturing supply agreement with Regeneron Pharmaceuticals, valued at over $3 billion. The deal has the Fujifilm subsidiary providing U.S.-based manufacturing for Regeneron, with planned expansions at Fujifilm’s large-scale biopharmaceutical manufacturing facility in Holly Springs, North Carolina.
Bayer invests $44M in Pennsylvania manufacturing plant

1 month ago | pharmaceuticalprocessingworld.com | Sean Whooley

Bayer announced today that it opened a 70,000-square-foot expansion at its Myerstown, Pennsylvania, facility. The grand opening of the state-of-the-art facility follows a $44 million investment in 2022. Bayer says it reflects its commitment to providing self-care solutions to consumers across North America while advancing meaningful engagement with the local community.
Novartis to expand U.S. manufacturing, R&D with $23B investment

1 month ago | pharmaceuticalprocessingworld.com | Sean Whooley

Novartis announced today that it plans to invest $23 billion over five years to expand its U.S.-based infrastructure. The company said its investment aims to ensure all key Novartis medicines for U.S. patients will be made in the U.S. Its financial commitment enables the company to expand on its current pharmaceutical manufacturing, research and technology presence across the company.
BDD Pharma opens new GMP manufacturing plant

2 months ago | pharmaceuticalprocessingworld.com | Sean Whooley

BDD announced today that it opened a new 122-square-meter GMP manufacturing facility at BioCity near Glasgow. The company opened its facility after two years of development following a successful inspection by the Medicines and Healthcare products Regulatory Authority (MHRA) last month. A £2 million funding round from existing investors facilitated the development of the state-of-the-art facility.